A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

October 12, 2026

Conditions

Epidermolysis Bullosa SimplexIchthyosisGenodermatosisInflammatory Congenital Ichthyoses

Interventions

DRUG

deucravacitinib

treatment by deucravacitinib in two phases of challenge

Trial Locations (2)

RECRUITING

APHP St Louis, Paris

RECRUITING

CHU de Nice, Nice

All Listed Sponsors

lead

Centre Hospitalier Universitaire de Nice

OTHER